Walleye Capital’s ALX Oncology ALXO Stock Holding History

Walleye Capital’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-400	Closed	-$4.46K	–	5542
2024 Q1	$4.46K	Buy	+400	New	+$5.62K	﹤0.01%	5172

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Walleye Capital's ALXO Position: Q4 2024 in Review

Walleye Capital sold out of ALX Oncology (ALXO) in Q4 2024, closing a stake of 230,875 shares — an estimated $420K sold.

Walleye Capital first reported a position in ALXO in Q4 2021 and held it in 5 quarters. The position peaked at $1.26M in Q4 2021. 87 funds tracked by Wall St. Rank hold ALXO as of Q4 2024.

Walleye Capital reported no remaining ALX Oncology position as of Q4 2024 after selling out during the quarter.
Walleye Capital sold 230,875 ALX Oncology shares in Q4 2024, an estimated $420K.
Walleye Capital first reported a position in ALX Oncology in Q4 2021 and held it in 5 quarters.
Walleye Capital's ALX Oncology position peaked at $1.26M in Q4 2021.
87 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.